EAACI Congress 2024

Back
31 May - 03 June 2024 Valencia, Spain

A randomized, double-blind, phase 2a study of covalent Bruton’s tyrosine kinase inhibitor TAS5315 in patients with chronic spontaneous urticaria with an inadequate response to H1-antihistamines

Friday 31 May, 17:45 PM - 17:57 PM Valencia, Spain